安定報道日時 2026-10-02 12:00
SCOPE-AD: AD診断における順序的コスト意識型順序信念計画
研究者たちは、順序的な証拠取得におけるコストと患者の負担を考慮したアルツハイマー病の診断に新しい手法SCOPE-ADを開発しました。
01
根拠
- AarXiv cs.AI一次情報2026-10-02 12:00
On ADNI, SCOPE-AD achieves 77.70\% Macro-F1 at an average acquisition cost of \$50.46, exceeding the strongest evaluated baseline by 9.34 percentage points.
- AarXiv cs.AI一次情報2026-10-02 12:00
On ADNI, SCOPE-AD achieves 77.70\% Macro-F1 at an average acquisition cost of \$50.46
- AarXiv cs.AI一次情報2026-10-02 12:00
Abstract: Alzheimer's disease (AD) diagnosis requires sequential evidence acquisition under heterogeneous test costs and patient burden. Fixed-modality predictors do not jointly decide which test to acquire or when the available evidence is sufficient for diagnosis. We propose SCOPE-AD (Sequential Cost-Aware Ordinal-Belief Planning with Energy-Based Models for Diagnostic Agents) for cost-aware cl…